

# In vitro assay for hepatic triglyceride accumulation

The pre-validation is divided into two steps : a transferability and a second phase on blind-coded substances (30 substances).

A study plan and a report will be required by each lab for each phase.

The assay will be performed with differentiated HepaRG - HPR116.

### **Quantitative information**

### **Transferability phase**

- **3 valid runs** (biological replicates) **per test item** are to be performed (a run is an independent experiment characterized by a new set of solutions and controls)
- 4 2 substances per plate (several plates are performed in a day)
- ↓ 1 full dose-response curve with positive control for each run
- 4 1 positive control + 3 test items
- 8 concentrations per substance will be screened (in quadruplicates) (examples of plate layout in *figure 2*)
- **Cytotoxicity** is measured for each plate

### <u>Phase II</u>

- **3 valid runs** (biological replicates) **per test item** are to be performed (a run is an independent experiment characterized by a new set of solutions and controls)
- 4 2 substances per plate (several plates are performed in a day)
- 4 1 full dose-response curve with positive control for each run
- 4 1 positive control + 30 test items
- 8 concentrations per substance will be screened (in quadruplicates) (examples of plate layout in *figure 2*)
- **Cytotoxicity** is measured for each plate



#### Quadruplicates

	1	2	3	4	5	6	7	8	9	10	11	12
A	PBS		C1	C2	СЗ	C4	C5	C6	C7	C8		PBS
В	PBS	Solvent									Positive control	PBS
С	PBS											PBS
D	PBS	control										PBS
E	PBS	(0.5 % DMSO)	C1	C2	СЗ	C4	C5	C6	C7	C8		PBS
F	PBS											PBS
G	PBS											PBS
Н	PBS											PBS

#### Figure 2 : Example of a plate layout (C=concentration)

### The offer should include:

- A contingency plan (including any changes about the workforce, work continuity during holidays...)
- ↓ A description of the quality system set up in the lab

## The offer should specify:

- ↓ The quantity of needed HepaRG HPR116 cells and corresponding media
- The associated cost